通过药物基因组学指导的倡议增加他类药物处方
Claire Rennie1, Mary Roads2, Bridger Bright3
1PGY2 Ambulatory Care Pharmacy Resident, Lexington Veterans Affairs Health Care System, Lexington, KY.
Journal of the American Pharmacists Association : JAPhA
|August 10, 2025
概括
药物基因组学测试有助于退伍军人开始使用他类药物治疗,改善其坚持性和耐受性. 这种遗传方法指导了个性化他类药物处方,克服了不耐受性的担忧.
科学领域:
- 药物基因组学 药物基因组学
- 临床药房 临床药房
- 提高质量 提高质量
背景情况:
- 低于最佳的他类药物治疗利用与不良影响的担忧和对他类药物不耐受性的遗传倾向有关.
- 需要个性化医疗方法来优化心血管疾病预防策略.
研究的目的:
- 为退伍军人实施药物基因组学测试,以指导他类药物治疗决策.
- 在退伍军人事务医疗保健系统 (VAHCS) 中增加适当的他类药物处方.
主要方法:
- 一项质量改进计划涉及药剂师通过个性化的电话提供药物基因组学测试和他类药物启动.
- 患者的坚持和耐受性至少在开始服用他类药物后四周被评估.
主要成果:
- 在107名患者中,50人开始使用他类药物治疗,其中45人 (90%) 完成了指导处方的药物基因组测试.
- 大多数患者 (72%) 在四周后报告了对他类药物治疗的良好坚持和耐受性.
结论:
- 药物基因组学测试可以增强以患者为中心的讨论和共享决策,在启动他类药物治疗.
- 基因组指导可能有助于在临床实践中成功实施他类药物治疗.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
871
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
871
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Genome-wide Association Studies-GWAS
14.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.2K
Pharmacodynamics: Overview and Principles
2.1K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.1K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114


